0H19 Stock Overview
A specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Orexo AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 9.60 |
| 52 Week High | SEK 22.45 |
| 52 Week Low | SEK 14.14 |
| Beta | 0.60 |
| 11 Month Change | -29.26% |
| 3 Month Change | -40.15% |
| 1 Year Change | -36.72% |
| 33 Year Change | -73.97% |
| 5 Year Change | -84.76% |
| Change since IPO | -83.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0H19 | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -5.5% | -1.1% | 1.0% |
| 1Y | -36.7% | -3.2% | 6.3% |
Return vs Industry: 0H19 underperformed the UK Pharmaceuticals industry which returned -3.2% over the past year.
Return vs Market: 0H19 underperformed the UK Market which returned 6.1% over the past year.
Price Volatility
| 0H19 volatility | |
|---|---|
| 0H19 Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0H19 has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0H19's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 113 | Nikolaj Sorensen | www.orexo.com |
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis.
Orexo AB (publ) Fundamentals Summary
| 0H19 fundamental statistics | |
|---|---|
| Market cap | SEK 324.35m |
| Earnings (TTM) | -SEK 105.30m |
| Revenue (TTM) | SEK 595.70m |
0.5x
P/S Ratio-3.1x
P/E RatioIs 0H19 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0H19 income statement (TTM) | |
|---|---|
| Revenue | SEK 595.70m |
| Cost of Revenue | SEK 69.80m |
| Gross Profit | SEK 525.90m |
| Other Expenses | SEK 631.20m |
| Earnings | -SEK 105.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | -3.05 |
| Gross Margin | 88.28% |
| Net Profit Margin | -17.68% |
| Debt/Equity Ratio | -1,688.6% |
How did 0H19 perform over the long term?
See historical performance and comparison